PAP Therapy vs Dental Device vs Atomoxetine-Oxybutynin for Obstructive Sleep Apnea

(ADAPT-OSA Trial)

This trial aims to determine which treatment option for obstructive sleep apnea (OSA) is most effective and easiest for patients to maintain. Participants will be randomly assigned to one of three treatments: PAP therapy (a machine that aids breathing during sleep), a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin, used to manage symptoms). Eligible participants should have been diagnosed with OSA within the last six months and experience symptoms like snoring or daytime sleepiness. Participants will attend two in-person visits and have four phone check-ins over a year to share experiences and report any side effects. As a Phase 4 trial, the treatments are already FDA-approved and proven effective, allowing researchers to understand how they benefit more patients.

The trial does not specify if you must stop taking your current medications, but you cannot participate if you are taking medications that don't mix well with atomoxetine or oxybutynin.

A previous study found that taking atomoxetine and oxybutynin together was safe and well-tolerated for people with obstructive sleep apnea (OSA) when used nightly for one month. Most participants experienced improvements in their condition without serious side effects, though some reported minor issues like dry mouth or trouble sleeping.

Positive Airway Pressure (PAP) therapy is generally well-tolerated. Research has shown no serious side effects, making it a safe choice for many. It is widely used for OSA and other conditions, indicating its safety for most people.

Oral appliance therapy, such as a sleep dental device, is another non-invasive treatment for OSA. It is usually well-tolerated, though some users report minor issues like dry mouth or jaw discomfort. Overall, it is a safe option for treating OSA.

Researchers are excited about these treatments for obstructive sleep apnea because they offer distinct alternatives to the usual continuous positive airway pressure (CPAP) therapy. The combination of atomoxetine and oxybutynin is particularly intriguing as it targets neurotransmitters to reduce airway collapse, offering a pharmacological approach that doesn’t require wearing a device during sleep. The sleep dental device is a comfortable, non-invasive option that physically repositions the jaw to keep airways open, making it appealing for those who can't tolerate traditional PAP machines. Each treatment provides a unique mechanism to tackle sleep apnea, potentially expanding the range of options available to patients.

This trial will compare three treatments for obstructive sleep apnea (OSA): Positive Airway Pressure (PAP) therapy, a sleep dental device, and the medication combination of atomoxetine-oxybutynin.

Studies have shown that PAP therapy effectively treats OSA by significantly reducing breathing disruptions during sleep and improving overall sleep quality. Research indicates that PAP therapy can lower the risk of death and reduce hospital visits.

Evidence shows that sleep dental devices can lessen OSA severity for many patients. They improve breathing during sleep and have high user satisfaction rates, though they may not be as effective as PAP for severe cases.